MediWound's Debrase hit two co-primary endpoints in its phase III trial and the trial will be stopped after treating the first 175 patients. Debrase will be marked by Teva and can be approved in Europe late next year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.